
RYZ101, a targeted alpha radiopharmaceutical, boosts progression-free survival in SSTR+ GEP-NETs after progression, offering a promising post-¹⁷⁷Lu option.
Metastatic Pancreatic Cancer With George P. Kim, MD, and Eileen M. O'Reilly, MD
Metastatic Pancreatic Cancer: Case 1
Larry D, a 62-year-old, presented to his primary care physician with persistent pain in his epigastric region, which persists throughout the night. Within the past 2 years, he has developed diabetes and experienced considerable weight loss with signs of depression.
Larry went on to receive the combination of nab-paclitaxel and gemcitabine as frontline therapy for 5 months:
Stay up to date on practice-changing data in community practice.
Subscribe
